Cannabis Breakthrough: Precise Cannabinoid Delivery
Any marketing guru will tell you that the most successful products are those that precisely meet the user’s needs while making as little fuss as possible. This has been a major issue in the cannabis market since day one because drug delivery methods were developed during an era of prohibition, forcing users to set fire to plants and inhale them in dark corners; hardly the peak of scientific accuracy and a big sticking point for would-be prescribers of the drug.
However, NanoSphere Health Sciences Inc. (CSE: NSHS) (“NanoSphere”) has created and patented a revolutionary route of administration that transports CBD, THC and other compounds directly into the bloodstream via the skin by coating each molecule in a lipid shell. This prevents the normal in-transit damage resulting from digestive acids and enzymes and allows direct transport throughout the body’s endocannabinoid system through external application.
Get our daily investorintel update
Since the legitimisation of marijuana products took hold, researchers have fought tooth-and-nail to bring efficacious solutions to market. Through its subsidiary Evolve Formulas, NanoSphere has tackled the normally-delayed onset of action, vastly increased the bioavailability of ingredients and alleviated adverse side effects of marijuana consumption, representing a major leap forward and a considerable value-add over the current range of cannabis-derived products on the market.
A study published in the National Academic Press at the beginning of 2017 highlighted the unreliability of administering a precise and effective dose of cannabis via either inhalation or digestion. There is simply no way to know how much active ingredient is finding the proper receptors due to a lack of standardisation. All plants vary in concentrations, everyone’s metabolic processes differ, and individuals continue to consume arbitrary and ambiguous doses at their leisure.
The tallest hurdle to market in this respect is therefore the ability to guarantee an exact and effective dose. Engineering particles for delivery down at the molecular level allows people to make informed decisions regarding self-medication. Someone seeking relief from anxiety at work, for instance, is going to want quite a different effect profile to a person seeking sound sleep. Similarly, those looking for freedom from nausea will likely need a little less than those suffering from chronic pain.
Moreover, these ailments are highly over-represented in people on the far-side of middle-age. This particular market segment is not as quick to buy cannabis-related medicines as, say, the dreaded millennials. Legitimate and trustworthy health products that perform exactly as advertised are required to bring the marijuana cynics over the border, and NanoSphere is, in our opinion, likely to capture a large portion of this nascent market over the next five years.
NanoSphere represents a compelling investment opportunity in the drug delivery space. With its new patent in place, the company is well-positioned to commercialise its breakthrough technology in both the cannabis industry and the wider nutraceutical and pharmaceutical industries. Furthermore, the market has yet to respond positively to the patent approval, but we expect this to change once the product hits the shelves in mid-May.
Interested investors would do well to keep a close eye NanoSphere as it pursues opportunities in these potentially lucrative markets. Companies that successfully break into the marijuana space are set to benefit from one of the fastest growing industries ever seen. In twenty years, the world will have gone green in more ways than one, and science is the cutting edge that can get us there.